Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The global burden of chronic Hepatitis B and the research to cure HBV
- Functional cure: the current goal for new therapies
- Emerging antiviral targets for HBV
- Emerging immunological targets for HBV
- Compounds currently under clinical evaluation
- New concepts of combination therapy to cure HBV
- Clinical trial designs to achieve an HBV cure
Topics Covered
- Research to cure HBV
- Goals for new therapies
- Emerging targets and compounds under clinical evaluation
- Combination therapy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Zoulim, F. (2022, January 30). The path towards a cure for chronic hepatitis B [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 12, 2024, from https://doi.org/10.69645/WLRU5078.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Zoulim consults for the following companies: Aligos, Antios, Arbutus, Assembly, Enochian, Gilead, GSK, Roche Molecular Systems and Zhimeng. He also receives research funding from INSERM to conduct research at Assembly Biosciences, Beam Therapeutics and Viravaxx AG.
A selection of talks on Gastroenterology & Nephrology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Professor Fabien Zoulim from Lyon University working at
the Hepatology Department of the Hospices Civils de Lyon and at INSERM U1052.
Today I will be giving a presentation on the path towards a cure for chronic hepatitis B.
0:20
Chronic HBV infection remains
a major public health problem with more than 250 million chronic carriers worldwide.
The elimination of HBV infection will require a concerted action,
with better vaccine coverage among the population,
and improved access to antiviral treatment to treat all chronic carriers.
Currently, the antiviral treatments are mainly suppressive,
they are not curative,
so the field of HBV has made a lot of
research to better understand the mechanism involved
in the molecular pathogenesis and
the viral persistence with experimental studies that were performed in
cultured hepatocytes, in humanized mouse studies,
and in patients with translational studies.
All these new insights
have allowed us to identify novel targets,
and have allowed us to discover novel antiviral drugs.
These studies have also allowed us to identify novel biomarkers and
the current clinical studies are evaluating the novel antiviral drugs and
immunotherapeutics with the help of the novel biomarkers to investigate whether
the new strategies will improve the cure rate of
infection and will improve the prevention of hepatocellular carcinoma.
As I've said, the current anti-viral treatments are mainly suppressive.